The European Commission (EC) has concluded an agreement of origin with Pfizer and BioNTech for two hundred million doses of their experimental vaccine candidate COVID-19 BNT162b2.
After the initial two hundred million doses of the mRN vaccine, the EC will also have the option to request another hundred million doses.
Deliveries of the first batches of the vaccine are expected to begin until the end of 2020, with continuous clinical good luck and regulatory approval of BNT162b2.
On Monday, Pfizer and BioNTech announced the initial effects of a Phase 3 of their COVID-19 vaccine, which showed that the vaccine prevented more than 90% of infections in vaccinated participants.
The interim investigation conducted after 94 test participants contracted COVID-19, and the review is expected to continue until 164 cases have occurred.
According to spouses’ companies, the case divided between vaccinated Americans and those who gained placebo indicates a vaccine effectiveness rate of more than 90%, seven days after the time dose of the vaccine.
Doses of BNT162b2 for Europe will be produced at BioNTech’s German production sites and Pfizer production sites in Belgium, corporations said at an earlier joint meeting.
They added that if BNT162b2 obtains approval from the European Medicines Agency (EMA), the doses will be ordered through the EU Member States that have selected to obtain the vaccine as a component of the agreement.
“As a company founded in central Europe, we look forward to offering millions of people after regulatory approval. We would like to thank the Commission and the Member States for their confidence in our COVID-19 candidate vaccine,” Ugur said. Sahin, CEO and co-founder of BioNTech.
“Our purpose is to expand an effective vaccine to help end this pandemic. Only through joint efforts can we do so,” he added.
On 20 July, Pfizer and BioNTech entered into an agreement with the UK to obtain 30 million doses of their BNT162b2 candidate vaccine.
A few days later, on July 22, corporations also agreed to provide up to six hundred million doses of vaccine to the United States after signing an agreement with the U. S. Department of Health and Human Services and the Department of Defense.
November 11, 2020
The European Commission will have the opportunity to request one hundred million more doses